Trials / Terminated
TerminatedNCT03866707
Epigenetic and Metabolomic Changes in Childhood Cancer Survivors
Epigenetic and Metabolomic Changes in Childhood Cancer Survivors as a Late Effect of Treatment - a Pilot Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 7 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to try and identify markers in childhood cancer survivors to help predict if they will develop late effects from their cancer treatment.
Detailed description
This is a pilot study to obtain preliminary data that will be used to apply for a larger grant to fund the full study with an adequate sample size for analysis. Specific Aim 1. What are the epigenetic differences between children treated for childhood cancers and healthy controls matched for age, sex, ethnicity, geographic region, and tanner stage. Specific Aim 2. Compare the metabolomic differences between children treated for childhood cancers and healthy controls matched for age, sex, ethnicity, geographic region, and tanner stage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | One-time blood draw | Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size. Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing. Metabolomic analysis will be performed by mass spectrometry when funds are available. |
| OTHER | Evaluation of CpG methylation | Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. |
| OTHER | Metabolomic analysis | Metabolomic analysis will be performed by mass spectrometry when funds are available. |
Timeline
- Start date
- 2019-02-25
- Primary completion
- 2020-05-16
- Completion
- 2020-05-16
- First posted
- 2019-03-07
- Last updated
- 2023-12-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03866707. Inclusion in this directory is not an endorsement.